What Drives Pharma Innovation Most: Academia, Biotech, Tech — or Patients?

As the life sciences industry accelerates its pursuit of next-generation therapies, partnerships have become more vital than ever.

From academic institutions advancing basic science, to nimble biotech startups pushing boundaries, to tech companies enabling data-driven breakthroughs — and patient advocacy groups shaping truly patient-centric solutions — the innovation landscape is increasingly collaborative.

Pharma companies are navigating a complex ecosystem, where choosing the right partnerships can unlock new scientific insights, accelerate drug development and improve outcomes. But which type of partnership delivers the most value for driving innovation forward?

This poll explores industry sentiment around which collaborators pharma should prioritize to stay competitive and responsive in today’s fast-evolving R&D environment.

Cast your vote below and join the conversation.

Related: Which Region Is Leading the Way in Life Sciences Innovation?